Disposition study of the novel dipeptidyl peptidase 4 inhibitor cetagliptin in rats

Abstract

1. Dipeptidyl peptidase-4 (DPP-4) inhibitor is a class of oral antihyperglycemic agents and therapeutic approach for type 2 diabetes. Cetagliptin is a novel oral and selective DPP-4 inhibitor and developed as a promising candidate for treatment of type 2 diabetes mellitus.

2. This study aimed to evaluate the metabolism and excretion of cetagliptin in Sprague-Dawley (SD) rats, and to detect and identify metabolites of cetagliptin.

3. The SD rats were administered with a single oral dose of 6 mg/kg with approximately 100 µCi of [¹⁴C] cetagliptin. The mean total recovery of radioactivity was 90.20% within 168h in SD rats excreta. Cetagliptin was the major radioactive component in SD rats plasma, urine and eliminated primarily by faecal excretion. The recovery of cetagliptin in urine and feces was 25.15% and 13.85% of the dose, respectively. Cetagliptin was well absorbed after oral administration in SD rats based on the total recovery of radioactivity in BDC SD rats bile and urine.

4. Six major metabolites were observed and identified in SD rats, comprising 0.20 to 4.53% of total plasma AUC. These major metabolites were the hydroxylated, N-sulphate and N-carbamoyl glucuronic acid conjugates of the cetagliptin, two metabolites formed by glucuronide of a hydroxylated metabolite.

Keywords:

• Cetagliptin
• metabolism
• excretion
• metabolite
• dipeptidyl peptidase-4 inhibitor

Disclosure statement

The authors report no declarations of interest.

Additional information

Funding

This work was supported by CGeneTech (Suzhou, China) Co., Ltd.